Overview

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).
Phase:
Phase 3
Details
Lead Sponsor:
Swedish Orphan Biovitrum
Collaborator:
CMIC Co, Ltd. Japan
Treatments:
Interleukin 1 Receptor Antagonist Protein